Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial
暂无分享,去创建一个
E. Oviedo-Orta | E. Mylonakis | F. Marty | D. Weinreich | G. Herman | R. Bhore | Shazia Ali | B. Hirshberg | E. Forleo-Neto | J. Hamilton | M. Hussein | Veronica Mas Casullo | Meagan P. O'Brien | A. Mahmood | A. Hooper | S. Somersan-Karakaya | Jenni Mou
[1] L. Akinbami,et al. SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[2] M. Kamboj,et al. SARS-CoV-2 in immunocompromised individuals , 2022, Immunity.
[3] W. Schaffner,et al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[4] B. Autran,et al. A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab , 2022, The Lancet Infectious Diseases.
[5] G. Yancopoulos,et al. Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies , 2022, medRxiv.
[6] Deepali Kumar,et al. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 (COVID-19) Outcomes in Organ Transplant Recipients During the Omicron Wave , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] E. André,et al. Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies. , 2022, medRxiv.
[8] Shinji Watanabe,et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 , 2022, The New England journal of medicine.
[9] V. Sintchenko,et al. Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use , 2022, The New England journal of medicine.
[10] M. Landray,et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[11] John D. Davis,et al. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19 , 2021, medRxiv.
[12] C. Chute,et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative , 2021, The Lancet Rheumatology.
[13] C. Munro. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines , 2021, BMJ.
[14] M. Storgaard,et al. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution , 2021, Open forum infectious diseases.
[15] Jennifer Abbasí. Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants. , 2021, JAMA.
[16] P. Malani,et al. Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019 , 2021, JAMA network open.
[17] M. Kaiser,et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma , 2021, The Lancet Haematology.
[18] A. Baum,et al. SARS-CoV-2 spike therapeutic antibodies in the age of variants , 2021, The Journal of experimental medicine.
[19] S. Fafi-Kremer,et al. SARS-CoV-2 viral dynamics in immunocompromised patients , 2020, American Journal of Transplantation.
[20] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[21] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[22] R. Harpaz,et al. Prevalence of Immunosuppression Among US Adults, 2013. , 2016, JAMA.